The Heart Institute of Good Samaritan Hospital and Division of Cardiovascular Medicine of the Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Cell Transplant. 2013;22(3):563-8. doi: 10.3727/096368911X627570. Epub 2012 Mar 27.
During the past 15 years, our research group has transplanted fetal/neonatal cardiomyocytes, mesenchymal stem cells, and embryonic stem cell-derived cardiomyocytes into infarcted myocardium in a rat myocardial infarction model. Our experimental data demonstrated that cell transplantation therapy provides a potential approach for the treatment of injured myocardium after myocardial infarction based on the reported positive effects upon histological appearance and left ventricular function. However, the underlying mechanisms of the benefits from cell transplantation therapy remain unclear and may involve replacement of scar tissue by transplanted cells, induced neoangiogenesis and paracrine effects of factors released by the transplanted cells. In this review, we summarize our experiences from experimental cell transplantation therapy in a rat myocardial infarction model and discuss the controversies and questions that need to be addressed in future studies.
在过去的 15 年中,我们的研究小组已经将胎儿/新生儿心肌细胞、间充质干细胞和胚胎干细胞衍生的心肌细胞移植到大鼠心肌梗死模型的梗死心肌中。我们的实验数据表明,细胞移植治疗为心肌梗死后受损心肌的治疗提供了一种潜在的方法,这基于对组织学外观和左心室功能的报告的积极影响。然而,细胞移植治疗益处的潜在机制尚不清楚,可能涉及移植细胞替代疤痕组织、诱导新血管生成和移植细胞释放的因子的旁分泌作用。在这篇综述中,我们总结了我们在大鼠心肌梗死模型中进行的实验性细胞移植治疗的经验,并讨论了未来研究中需要解决的争议和问题。